In a significant move for the biotech industry, the One Big Beautiful Bill Act has been enacted, reinstating the full deduction of research and development (R&D) expenses. As emphasized in the official statement, this legislation, signed into law in early July 2023, is poised to provide much-needed financial relief to biotech firms that heavily invest in innovation.
Restoration of R&D Expense Deduction
The restoration of the 100% R&D expense deduction is designed to bolster domestic industries by easing the financial burdens that biotech companies face. These firms typically allocate a substantial portion of their budgets to research and development, making the deduction a crucial factor in their financial planning.
Encouraging Investment in Innovation
By alleviating short to midterm financial pressures, the act aims to encourage further investment in R&D, ultimately fostering innovation and growth within the sector. This legislative change is expected to have a positive impact on the biotech landscape, potentially leading to advancements in medical research and technology.
In a related development, Lighter has successfully raised $68 million to enhance its position in the decentralized derivatives market. For more details, see the full article here.
